There IS a clear roadmap towards clinic as indicated below in the Corporate Overview June 2018: .....
DX1 pharmacokinetics in triple negative breast cancer June 2018
Initiate stable cell line development of PAT-DX1 H2 2018
DX1 - Solid cancer (TBC) animal data August 2018
Select target indication for PAT-DX1 clinical development Q3 2018
DX1 – Additional solid cancer (TBC) animal data October 2018
DX1 + Temozolomide + radiation – brain cancer animal data Q4 2018
Please note that target indication for clinic development may be determined this quarter, perhaps shortly after the ann of Solid cancer animal data in Aug.
In addition, the latest ann is about PAT-DX1 while the one released on 29 Jan is about PAT-DX1-NP. Please do some research to understand the differences between these two things.
Actually, the latest ann discloses the further pre-clinical development about PAT-DX1 against TNBC and is consistent with the ann released on 14 Sep 2017 that says "Patrys has also completed the first animal study using PAT-DX1, in a mouse model of triple negative breast cancer. These studies have shown signals of efficacy and will act as guidance for dosing and route of administration for PAT-DX1 in future animal studies."
(20min delay)